Free Trial
NASDAQ:EQRX

EQRx (EQRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.34
$2.34
50-Day Range
$2.04
$2.47
52-Week Range
$1.58
$5.55
Volume
N/A
Average Volume
3.30 million shs
Market Capitalization
$1.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EQRX stock logo

About EQRx Stock (NASDAQ:EQRX)

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.

EQRX Stock News Headlines

Gubra AS GUBRA
The World Has Its Way With EQRx
Q1 2023 EQRx Inc Earnings Call
See More Headlines
Receive EQRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:EQRX
Fax
N/A
Employees
362
Year Founded
N/A

Profitability

Net Income
$-169,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.40 per share

Miscellaneous

Free Float
398,218,000
Market Cap
$1.14 billion
Optionable
Optionable
Beta
0.48
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Alexis A. Borisy A.M. (Age 51)
    Founder & Executive Chairman of Board of Directors
  • Ms. Melanie I. Nallicheri (Age 54)
    President, CEO, Principal Executive & Financial Officer and Director
    Comp: $931.75k
  • Ms. Dina Ciarimboli J.D. (Age 54)
    General Counsel & Corporate Secretary
    Comp: $628.63k
  • Mr. Robert Forrester LL.B. (Age 59)
    Co-Founder & Advisor
  • Dr. Peter B. Bach M.D. (Age 58)
    MAPP, Co-Founder & Advisor
  • Sir Andrew Dillon CBE
    Co-Founder & Advisor
  • Mr. Daniel Hoey (Age 56)
    Chief of Technical Operations
  • Ms. Rona Anhalt (Age 58)
    Chief People Officer
  • Dr. Carlos Garcia-Echeverria Ph.D. (Age 58)
    Chief of RX Creation
  • Dr. Eric E. Hedrick M.D. (Age 58)
    Chief Physician Executive
    Comp: $575.1k

This page (NASDAQ:EQRX) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners